MA55015A - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques

Info

Publication number
MA55015A
MA55015A MA055015A MA55015A MA55015A MA 55015 A MA55015 A MA 55015A MA 055015 A MA055015 A MA 055015A MA 55015 A MA55015 A MA 55015A MA 55015 A MA55015 A MA 55015A
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
MA055015A
Other languages
English (en)
Inventor
René Holm
Kristof Leonard Kimpe
Audrey Antoinette Renée Lathuile
Thomas Eddy R Neefs
Hana Prokopcová
Sanket Manoj Shah
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA55015A publication Critical patent/MA55015A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055015A 2019-02-22 2020-02-20 Formulations pharmaceutiques MA55015A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019075844 2019-02-22

Publications (1)

Publication Number Publication Date
MA55015A true MA55015A (fr) 2021-12-29

Family

ID=69650609

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055015A MA55015A (fr) 2019-02-22 2020-02-20 Formulations pharmaceutiques

Country Status (21)

Country Link
US (1) US20220175760A1 (fr)
EP (1) EP3927324A1 (fr)
JP (1) JP2022523371A (fr)
KR (1) KR20210132099A (fr)
CN (1) CN113473971B (fr)
AU (1) AU2020225342A1 (fr)
BR (1) BR112021016411A2 (fr)
CA (1) CA3129356A1 (fr)
CR (1) CR20210480A (fr)
EA (1) EA202192322A1 (fr)
EC (1) ECSP21067816A (fr)
IL (1) IL285674A (fr)
JO (1) JOP20210230A1 (fr)
MA (1) MA55015A (fr)
MX (1) MX2021010144A (fr)
PE (1) PE20212323A1 (fr)
PH (1) PH12021552020A1 (fr)
SG (1) SG11202109102PA (fr)
TW (1) TW202045159A (fr)
UY (1) UY38593A (fr)
WO (1) WO2020169738A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
EP3953345B1 (fr) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Dérivés de pyridines comme inhibiteurs de malt1
KR20230054394A (ko) 2020-08-21 2023-04-24 얀센 파마슈티카 엔.브이. 비정질 형태의 malt1 억제제 및 이의 제형
EP4199911A1 (fr) * 2020-08-21 2023-06-28 JANSSEN Pharmaceutica NV Formulations pharmaceutiques comprenant un inhibiteur de malt1 et un mélange de polyéthylèneglycol et d'un acide gras
WO2022185097A1 (fr) * 2021-03-03 2022-09-09 Janssen Pharmaceutica Nv Méthode de traitement d'une affection à l'aide d'une dose thérapeutiquement efficace de l'inhibiteur de malt1 jnj-67856633 (1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluorométhyl)-n-(2-(trifluorométhyl)pyridin-4-yl)-1 h-pyrazole-4-carboxamide)
AU2022425324A1 (en) * 2021-12-30 2024-05-30 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Tricyclic derivative inhibitor, preparation method therefor, and application thereof
WO2025073968A1 (fr) 2023-10-06 2025-04-10 Ionctura Sa Combinaison de roginolisib avec un inhibiteur de malt1-gls

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2006037348A1 (fr) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Compositions pharmaceutiques contenant du fenofibrate et une statine
US9789187B2 (en) * 2009-02-11 2017-10-17 Cadila Pharmaceuticals Limited Stable pharmaceutical composition for atherosclerosis
WO2010118078A1 (fr) * 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
EA201492082A1 (ru) * 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CN107296807B (zh) * 2016-04-15 2020-03-20 中国科学院上海生命科学研究院 Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物

Also Published As

Publication number Publication date
JOP20210230A1 (ar) 2023-01-30
TW202045159A (zh) 2020-12-16
CA3129356A1 (fr) 2020-08-27
SG11202109102PA (en) 2021-09-29
CN113473971B (zh) 2024-07-02
MX2021010144A (es) 2021-09-14
AU2020225342A1 (en) 2021-08-19
IL285674A (en) 2021-10-31
WO2020169738A1 (fr) 2020-08-27
CN113473971A (zh) 2021-10-01
KR20210132099A (ko) 2021-11-03
BR112021016411A2 (pt) 2021-10-13
EP3927324A1 (fr) 2021-12-29
PE20212323A1 (es) 2021-12-14
CR20210480A (es) 2021-11-10
ECSP21067816A (es) 2021-12-30
PH12021552020A1 (en) 2022-09-12
JP2022523371A (ja) 2022-04-22
EA202192322A1 (ru) 2021-12-03
UY38593A (es) 2020-08-31
US20220175760A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
EP4045480A4 (fr) Formulations pharmaceutiques
IL283134A (en) Alcohol-resistant drug formulations
EP3817722A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
MA52421A (fr) Composés pharmaceutiques
MA55015A (fr) Formulations pharmaceutiques
MA50541A (fr) Formulations pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
DK3927315T3 (da) Velsmagende formuleringer
DK3886820T3 (da) Kapselformuleringer
EP3946316A4 (fr) Compositions pharmaceutiques de cannabidiol
MA49837A (fr) Compositions pharmaceutiques
EP4015001A4 (fr) Composition pharmaceutique orale
DK3908321T3 (da) Farmaceutisk sammensætning
EP3746080A4 (fr) Formulations pharmaceutiques
EP3337463A4 (fr) Formulations pharmaceutiques
MA54095A (fr) Formulations pharmaceutiques aqueuses
DK4027973T3 (da) Formuleringer til lægemiddeladministration
DK3911298T3 (da) Formuleringer
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
PT3949952T (pt) Composição farmacêutica
EP3651800A4 (fr) Formulations pharmaceutiques hydrocompressées
EP3920909A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
CR20220587A (es) Formulaciones farmacéuticas
EP3638211A4 (fr) Compositions pharmaceutiques à libération prolongée retardée